Literature DB >> 25560532

Breast cancer in 2014: A call back to reality!

Fatima Cardoso1, Elżbieta Senkus2.   

Abstract

In 2014, no major breakthroughs were made in understanding the biology of breast cancer or its management; few novel practice-changing studies were presented or published. Nevertheless, important negative results from studies that challenge some of the current concepts, particularly in drug development, underline 2014 as a year of ‘failed surrogates and precocious expectations’.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25560532     DOI： 10.1038/nrclinonc.2014.226

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  5 in total

1.  Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER).

Authors:  Fabrice André; Thomas Bachelot; Frederic Commo; Mario Campone; Monica Arnedos; Véronique Dieras; Magali Lacroix-Triki; Ludovic Lacroix; Pascale Cohen; David Gentien; Jose Adélaide; Florence Dalenc; Anthony Goncalves; Christelle Levy; Jean-Marc Ferrero; Jacques Bonneterre; Claudia Lefeuvre; Marta Jimenez; Thomas Filleron; Hervé Bonnefoi
Journal:  Lancet Oncol       Date:  2014-02-07       Impact factor: 41.316

2.  ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).

Authors:  F Cardoso; A Costa; L Norton; E Senkus; M Aapro; F André; C H Barrios; J Bergh; L Biganzoli; K L Blackwell; M J Cardoso; T Cufer; N El Saghir; L Fallowfield; D Fenech; P Francis; K Gelmon; S H Giordano; J Gligorov; A Goldhirsch; N Harbeck; N Houssami; C Hudis; B Kaufman; I Krop; S Kyriakides; U N Lin; M Mayer; S D Merjaver; E B Nordström; O Pagani; A Partridge; F Penault-Llorca; M J Piccart; H Rugo; G Sledge; C Thomssen; L Van't Veer; D Vorobiof; C Vrieling; N West; B Xu; E Winer
Journal:  Breast       Date:  2014-09-20       Impact factor: 4.380

3.  Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.

Authors:  M Piccart; G N Hortobagyi; M Campone; K I Pritchard; F Lebrun; Y Ito; S Noguchi; A Perez; H S Rugo; I Deleu; H A Burris; L Provencher; P Neven; M Gnant; M Shtivelband; C Wu; J Fan; W Feng; T Taran; J Baselga
Journal:  Ann Oncol       Date:  2014-09-17       Impact factor: 32.976

Review 4.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

Authors:  Patricia Cortazar; Lijun Zhang; Michael Untch; Keyur Mehta; Joseph P Costantino; Norman Wolmark; Hervé Bonnefoi; David Cameron; Luca Gianni; Pinuccia Valagussa; Sandra M Swain; Tatiana Prowell; Sibylle Loibl; D Lawrence Wickerham; Jan Bogaerts; Jose Baselga; Charles Perou; Gideon Blumenthal; Jens Blohmer; Eleftherios P Mamounas; Jonas Bergh; Vladimir Semiglazov; Robert Justice; Holger Eidtmann; Soonmyung Paik; Martine Piccart; Rajeshwari Sridhara; Peter A Fasching; Leen Slaets; Shenghui Tang; Bernd Gerber; Charles E Geyer; Richard Pazdur; Nina Ditsch; Priya Rastogi; Wolfgang Eiermann; Gunter von Minckwitz
Journal:  Lancet       Date:  2014-02-14       Impact factor: 79.321

5.  Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

Authors:  Olivia Pagani; Meredith M Regan; Barbara A Walley; Gini F Fleming; Marco Colleoni; István Láng; Henry L Gomez; Carlo Tondini; Harold J Burstein; Edith A Perez; Eva Ciruelos; Vered Stearns; Hervé R Bonnefoi; Silvana Martino; Charles E Geyer; Graziella Pinotti; Fabio Puglisi; Diana Crivellari; Thomas Ruhstaller; Eric P Winer; Manuela Rabaglio-Poretti; Rudolf Maibach; Barbara Ruepp; Anita Giobbie-Hurder; Karen N Price; Jürg Bernhard; Weixiu Luo; Karin Ribi; Giuseppe Viale; Alan S Coates; Richard D Gelber; Aron Goldhirsch; Prudence A Francis
Journal:  N Engl J Med       Date:  2014-06-01       Impact factor: 91.245
  5 in total
  2 in total

Review 1.  Advancing Immunotherapy in Metastatic Breast Cancer.

Authors:  Mariam Mansour; Zhi Ling Teo; Stephen J Luen; Sherene Loi
Journal:  Curr Treat Options Oncol       Date:  2017-06

2.  Trends and outcomes of neoadjuvant radiotherapy compared with postoperative radiotherapy for malignant breast cancer.

Authors:  Wenyan Fu; Hefen Sun; Yang Zhao; Mengting Chen; Lipeng Yang; Shuiping Gao; Liangdong Li; Wei Jin
Journal:  Oncotarget       Date:  2018-05-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.